DexCom (NASDAQ:DXCM) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Tuesday.

DXCM has been the subject of a number of other research reports. BMO Capital Markets reissued an “outperform” rating and set a $62.00 price objective (down previously from $90.00) on shares of DexCom in a research report on Thursday, September 28th. Raymond James Financial cut DexCom from an “outperform” rating to a “mkt perform” rating in a research report on Friday, September 29th. Canaccord Genuity reissued a “buy” rating and set a $69.00 price objective (down previously from $90.00) on shares of DexCom in a research report on Thursday, September 28th. TheStreet cut DexCom from a “c-” rating to a “d+” rating in a research report on Wednesday, October 25th. Finally, ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. DexCom presently has an average rating of “Buy” and an average price target of $71.36.

DexCom (NASDAQ:DXCM) traded up $1.26 on Tuesday, reaching $58.51. The company had a trading volume of 1,206,600 shares, compared to its average volume of 1,456,272. DexCom has a 52-week low of $42.62 and a 52-week high of $88.80. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84.

In other news, EVP Steven Robert Pacelli sold 1,450 shares of DexCom stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $69.81, for a total value of $101,224.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $69.34, for a total value of $416,040.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,955 shares of company stock worth $2,583,643. Corporate insiders own 1.70% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Winslow Capital Management LLC bought a new position in shares of DexCom in the second quarter worth about $117,451,000. State Street Corp grew its position in DexCom by 2.5% during the second quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock worth $113,374,000 after buying an additional 37,581 shares in the last quarter. Peregrine Capital Management LLC grew its position in DexCom by 24.5% during the third quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock worth $19,348,000 after buying an additional 77,868 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in DexCom by 111.6% during the second quarter. BNP Paribas Arbitrage SA now owns 9,471 shares of the medical device company’s stock worth $693,000 after buying an additional 4,995 shares in the last quarter. Finally, Macquarie Group Ltd. grew its position in DexCom by 67.2% during the second quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock worth $17,746,000 after buying an additional 97,479 shares in the last quarter.

WARNING: This news story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/14/bidaskclub-upgrades-dexcom-dxcm-to-strong-buy.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Stock Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related stocks with our FREE daily email newsletter.